These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17704319)

  • 1. "Stability" of gadolinium chelates.
    Tweedle MF
    Br J Radiol; 2007 Jul; 80(955):583-4; author reply 584-5. PubMed ID: 17704319
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of thermodynamic and kinetic parameters in gadolinium chelate stability.
    Idée JM; Port M; Robic C; Medina C; Sabatou M; Corot C
    J Magn Reson Imaging; 2009 Dec; 30(6):1249-58. PubMed ID: 19938037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: chemical structure and stability of gadolinium chelates.
    Idée JM; Port M; Corot C
    Radiographics; 2009 Nov; 29(7):2099. PubMed ID: 19926764
    [No Abstract]   [Full Text] [Related]  

  • 4. Stability of linear and macrocyclic gadolinium based contrast agents.
    Schmitt-Willich H
    Br J Radiol; 2007 Jul; 80(955):581-2; author reply 584-5. PubMed ID: 17704318
    [No Abstract]   [Full Text] [Related]  

  • 5. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance.
    Runge VM; Ai T; Hao D; Hu X
    Invest Radiol; 2011 Dec; 46(12):807-16. PubMed ID: 22094366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular gadolinium contrast agents: differences in stability.
    Morcos SK
    Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties.
    Ladd DL; Hollister R; Peng X; Wei D; Wu G; Delecki D; Snow RA; Toner JL; Kellar K; Eck J; Desai VC; Raymond G; Kinter LB; Desser TS; Rubin DL
    Bioconjug Chem; 1999; 10(3):361-70. PubMed ID: 10346865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
    Puerta DT; Botta M; Jocher CJ; Werner EJ; Avedano S; Raymond KN; Cohen SM
    J Am Chem Soc; 2006 Feb; 128(7):2222-3. PubMed ID: 16478170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.
    Idée JM; Fretellier N; Robic C; Corot C
    Crit Rev Toxicol; 2014 Nov; 44(10):895-913. PubMed ID: 25257840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergic reactions to gadolinium chelates.
    Runge VM
    AJR Am J Roentgenol; 2001 Oct; 177(4):944-5. PubMed ID: 11566710
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of approved MR contrast media for intravenous injection.
    Runge VM
    J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleavable β-cyclodextrin nanocapsules incorporating Gd(III)-chelates as bioresponsive MRI probes.
    Martinelli J; Fekete M; Tei L; Botta M
    Chem Commun (Camb); 2011 Mar; 47(11):3144-6. PubMed ID: 21270985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents.
    Maiocchi A
    Mini Rev Med Chem; 2003 Dec; 3(8):845-59. PubMed ID: 14529503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.
    Blomqvist L; Nordberg GF; Nurchi VM; Aaseth JO
    Biomolecules; 2022 May; 12(6):. PubMed ID: 35740867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Physico-chemical and toxicological profile of gadolinium chelates as contrast agents for magnetic resonance imaging].
    Idée JM; Fretellier N; Thurnher MM; Bonnemain B; Corot C
    Ann Pharm Fr; 2015 Jul; 73(4):266-76. PubMed ID: 25731664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic gadolinium-based contrast agents: the future?
    Thomsen HS
    Acta Radiol; 2017 Nov; 58(11):1285-1287. PubMed ID: 28691527
    [No Abstract]   [Full Text] [Related]  

  • 19. Introduction.
    Martin DR
    Top Magn Reson Imaging; 2016 Dec; 25(6):255. PubMed ID: 27849655
    [No Abstract]   [Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: a chemical perspective.
    Rofsky NM; Sherry AD; Lenkinski RE
    Radiology; 2008 Jun; 247(3):608-12. PubMed ID: 18487530
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.